As of August 2022, Igenesis has submitted 105 patent applications and 78 of which have been approved by China Intellectual Property Office, including 11 invention patents, 29 utility model patents, 27 industrial design patents and 9 software copyrights. Besides, Igenesis has submitted 5 international PCT patent applications and 1 of which has been approved by EU. In addition, Igenesis owns 12 trademarks. Multiple products have been approved by CFDA and EU. Igenesis's innovative molecular diagnostic technologies and products have been highly recognized by the state.
In 2018, Igenesis signed a contract with China CDC in the "13th Five-Year" National Science and Technology major project, and jointly participated the research of "Multi-center Evaluation of Tuberculosis Multiple Combination Diagnostic Technology".
In 2020, Igenesis was awarded as "High-tech Enterprise of China". In the same year, Igenesis was listed as one of the emergency taking companies for the prevention and control of COVID-19 by Shanghai Municipal Economic and Information Commission.
In 2021, the product of Galaxy Nano was listed as "Shanghai High-tech Achievement Transformation Project".
Igenesis has around 150 employees, half of which are R&D staff. The company keeps spending a lot in R&D every year, and the products have been widely sold around the world.
中文
